These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2314611)

  • 1. [IgD myeloma. Presentation of a case and review of the literature].
    Fiore G; Baraldi A; Cremonte LG; Marenco M
    Minerva Med; 1990; 81(1-2):103-5. PubMed ID: 2314611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term complete remission in IgD-myeloma.
    Bemelmans RH; van Toorn DW; van Leeuwen L; Schaar CG
    Eur J Haematol; 2006 Apr; 76(4):339-41. PubMed ID: 16519706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgD multiple myeloma. A report of three cases.
    Martini R; Santini S; Bottari G
    Minerva Med; 1996 Mar; 87(3):109-12. PubMed ID: 8668286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pleural effusion as a first sign of Ig D lambda multiple myeloma].
    Maachi M; Fellahi S; Diop ME; Francois T; Capeau J; Bastard JP
    Ann Med Interne (Paris); 2003 Feb; 154(1):70-2. PubMed ID: 12746663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis and therapy of multiple myeloma: current aspects].
    Betticher DC; Cerny T; Fey MF
    Schweiz Med Wochenschr; 1995 Mar; 125(11):541-51. PubMed ID: 7899848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
    Nozza A; Siracusano L; Armando S
    Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Myelomatosis. A study of 138 patients treated with melphalan, prednisone and vincristine with particular attention to the prognostic value of a stage subdivision].
    Johnsen HE; Bergmann OJ; Boesen AM; Pedersen BB; Ellegaard J; Bastrup-Madsen P
    Ugeskr Laeger; 1989 Mar; 151(13):816-21. PubMed ID: 2718264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment.
    Takemori N; Kondo K; Kawamura T; Imai K; Sakurai H; Sato T
    Am J Hematol; 2001 Jan; 66(1):62-3. PubMed ID: 11426497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Polychemotherapy versus melphalan-prednisone in multiple myeloma].
    Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A
    G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590
    [No Abstract]   [Full Text] [Related]  

  • 11. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Smoldering myeloma].
    Dolgos J; Patakfalvi A
    Orv Hetil; 1993 Sep; 134(39):2155-7. PubMed ID: 8414460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of multiple myeloma].
    La Verde G; Pulsoni A; Petrucci MT; Mandelli F
    Recenti Prog Med; 1997 Apr; 88(4):186-93. PubMed ID: 9206817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma index: verification of a new prognostic approach with evaluation of treatment response.
    Bettini R; Tonolini M; Bernasconi M
    Haematologica; 1998 Aug; 83(8):708-13. PubMed ID: 9793254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternating intravenous courses of melphalan and peptichemio in high-risk multiple myeloma (preliminary results).
    Franchi F; Seminara P; Rossi Fanelli F
    Anticancer Res; 1986; 6(2):297-8. PubMed ID: 3707066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Multiple myeloma. Biological, prognostic, and therapeutic aspects].
    Corrado C; Pavlovsky S
    Sangre (Barc); 1990 Aug; 35(4):289-97. PubMed ID: 1703328
    [No Abstract]   [Full Text] [Related]  

  • 17. [A case of gastric amyloidosis developing into Bence-Jones type multiple myeloma, treated effectively by cyclo-VAMP chemotherapy].
    Ayabe T; Maekawa I; Ashida T; Taruishi M; Shibata Y; Namiki M
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2399-403. PubMed ID: 8259860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [An elderly patient with IgD myeloma associated with renal amyloidosis and acute renal failure].
    Kiyatake I; Tomino Y; Funabiki K; Kubokawa Y; Shirato I; Kubota M; Koide H
    Nihon Jinzo Gakkai Shi; 1989 Jul; 31(7):791-6. PubMed ID: 2511365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myeloma with extramedullary extension coinciding with the normalization of serum paraproteins after treatment].
    Bernat S; Gozalbo T; García-Boyero R; Guinot M
    Sangre (Barc); 1998 Feb; 43(1):96-7. PubMed ID: 9577192
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.